ProCE Banner Activity

Phase II Trial of Crenolanib and 7+3 Chemotherapy in Newly Diagnosed FLT3-Mutated AML: Long-term Results

Slideset Download
Conference Coverage
Patients with newly diagnosed FLT3-mutated AML demonstrated high overall response rates and high 3-year EFS and OS rates with crenolanib plus 7+3 after a median follow-up of 45 months.

Released: June 17, 2022

Expiration: June 16, 2023

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

GlaxoSmithKline

Jazz Pharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Seagen

Seagen and Genmab